Charles River Laboratories Intl. Inc vs Alphabet Inc Class A — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Alphabet Inc Class A trades at $343.44 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 312× Charles River Laboratories Intl. Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GOOGL | |
|---|---|---|
Market Cap | $13.46B | $4.20T |
Sector | Health | Media |
52-Week High | $282.00 | $402.62 |
52-Week Low | $145.57 | $199.32 |
Enterprise Value | $16.30B | $4.09T |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Alphabet (GOOGL) is trading at $343.80, down 3.84% amid broader tech sector rotation. Despite the recent decline, the company maintains strong fundamentals with 2025 revenue of $402.84B and net income of $132.17B, representing a 32.8% profit margin. Technical indicators show bearish momentum with the stock testing support near $341, while analyst consensus remains overwhelmingly bullish with an 85% buy rating and $426.28 price target. Recent quarterly earnings have consistently exceeded expectations, with Q2 2026 EPS of $9.11 beating estimates by 217%.
The outlook remains positive given Alphabet's dominant market position, AI leadership, and strong cash flow generation. Key risks include antitrust scrutiny and tech sector volatility. With the stock trading below consensus targets and showing robust earnings growth, current levels present a potential entry point for long-term investors seeking exposure to AI and digital advertising growth.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →